## INCIDENCE OF SUPRAVENTRICULAR ARRHYTHMIAS IN ACUTE EXACERBATIONS OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE PATIENTS AND ITS IMPACT ON OUTCOME

Tamer A.Helmy, Samir M. Al Awady, Mary Magdy.

#### Critical Care Medicine Department, Faculty of Medicine, Alexandria University, Alexandria, Egypt.

# Introduction

Supraventricular and ventricular arrhythmias as well as conduction disturbances of varying severity are frequently observed in chronic obstructive pulmonary disease (COPD). The type of arrhythmia that occurs in patients with COPD is affected by their clinical state. The risk is further elevated during periods of acute exacerbation however, even patients with stable COPD have a fairly high rate of rhythm disturbances. COPD shares a lot of risk factors (e.g., age, smoking) with a number of disease processes and related treatment that are also associated with cardiac arrhythmias. Patients who develop supraventricular arrythmias had longer ICU and hospital stay and increased mortality rates.

# Aim of the work

The aim of this study was to prospectively assess the incidence of supraventricular arrhythmias during acute exacerbations of chronic obstructive pulmonary disease, to identify the associated factors, and to evaluate its impact on hemodynamics and outcome of patients..

# Patients and Methods

A prospective cohort study was conducted that enrolled 100 mechanically ventilated patients with acute exacerbation of COPD (AECOPD). The patients were categorized into two groups based on the development of supraventricular arrythmias. The first group (SVT Group) who developed supraventricular tachycardia or supraventricular arrythmias other than sinus tachycardia. The second group (SR Group) who maintained sinus rhythm. The outcome included: need for mechanical ventilation (MV), duration of ICU stays, need for vasopressors and mortality.

## Results

66 patients developed supraventricular tachycardia (SVT Group) and 34 patients-maintained sinus rhythm (SR Group)

Table (1):Comparison between group 1 (SVT) and group 2 (SR) according to serum ionized Ca, phosphorus and magnesium (mg/dl) on the 1<sup>st</sup>, 3<sup>rd</sup> and 6<sup>th</sup> days of follow up.

		Group 1 (SVT)	Group 2 (SR)	Test of Sig.	p
Ca (mg/dl)	1st day	(n = 66)	(n = 34)		
	Min. – Max.	2.0 - 5.40	0.80 - 5.20	t= 2.482*	0.015*
	Mean $\pm$ SD.	$3.93 \pm 0.97$	$4.46 \pm 1.11$		
	3 <sup>rd</sup> day	(n = 66)	(n = 34)		
	Min. – Max.	3.50 - 5.20	0.90 - 5.0	t= 0.304	0.762
	Mean $\pm$ SD.	$4.43 \pm 0.53$	$4.48 \pm 0.94$		
	6 <sup>th</sup> day	(n = 52)	(n = 18)		
	Min. – Max.	3.60 - 5.0	4.40 - 5.0	t= 0.299	0.766
	Mean $\pm$ SD.	$4.60 \pm 0.33$	$4.62 \pm 0.17$		
Phosphorus (mg/dl)	1st Day	(n = 66)	(n = 34)		
	Median (Min. –	2.80 (1.10 –	3.20 (2.50 –	U= 822.0*	0.029*
	Max.)	5.20)	7.0)		
	Mean $\pm$ SD.	$2.87 \pm 0.95$	$3.47\pm1.27$		
	3 <sup>rd</sup> day	(n = 66)	(n = 34)		
	Median (Min. –	2.60 (0.80 -	3.0 (2.70 –	U= 689.00*	0.002*
	Max.)	7.0)	6.50)		
	Mean $\pm$ SD.	$3.05 \pm 1.58$	$3.46 \pm 1.12$		
	6 <sup>th</sup> day	(n = 52)	(n = 18)		
	Median (Min. –	3.0 (1.60 –	3.0 (2.50 –	U= 393.0	0.308
	Max.)	7.0)	6.50)		
	Mean $\pm$ SD.	$3.62 \pm 1.52$	$3.21 \pm 1.22$	373.0	
Magnesium (mg/dl)	1 <sup>st</sup> day	(n = 66)	(n = 34)		
	Min. – Max.	0.50 - 2.0	1.20 - 2.0	t= 3.153*	0.002*
	Mean $\pm$ SD.	$1.59 \pm 0.38$	$1.78 \pm 0.21$		
	3 <sup>rd</sup> day	(n = 66)	(n = 34)		
	Min. – Max.	1.30 - 2.0	1.80 - 2.10	t=	< 0.001
	Mean $\pm$ SD.	$1.72 \pm 0.20$	$1.89 \pm 0.10$	5.921*	*
	6 <sup>th</sup> day	(n = 52)	(n = 18)		
	Min. – Max.	1.50 - 2.0	1.50 - 2.10	t= 2.659*	0.014*
	Mean $\pm$ SD.	$1.74 \pm 0.14$	$1.88 \pm 0.21$		




MEDICINE

2022©Alexandria Faculty of Medicine CC-BY-NC

Table (2):Comparison between group 1 (SVT) and group 2 (SR) according to different parameters of outcome.

	Total (n = 100)	Group 1 (SVT) (n = 66)	Group 2 (SR) (n = 34)	Test of Sig.	р
MV					
NIV	36 (36.0%)	16 (24.2%)	20 (58.8%)	x <sup>2</sup> =	
Invasive	46 (46.0%)	35 (53.0%)	11 (32.4%)	x 11.950*	0.003*
Both	18 (18.0%)	15 (22.7%)	3 (8.8%)	11.750	
MV days					
Median (Min Max.)	4.0 (2.0 - 20.0)	5.50 (2.0 - 20.0)	3.0 (2.0 - 8.0)	U=	<0.001*
Mean ± SD.	5.93 ± 4.33	7.23 ± 4.73	3.41 ± 1.54	481.50 <sup>*</sup>	\0.001
ICU stay					
Median (Min Max.)	6.0 (3.0 - 20.0)	7.0 (4.0 - 20.0)	4.50 (3.0 - 8.0)	U= 393.50*	<0.001*
Mean ± SD.	7.14 ± 3.89	8.38 ± 4.15	4.74 ± 1.58		
Hospital stay					
Median (Min Max.)	7.0 (3.0 - 20.0)	8.0 (4.0 - 20.0)	6.0 (3.0 - 11.0)	U= 452.00*	<0.001*
Mean ± SD.	8.18 ± 3.72	9.35 ± 3.91	5.91 ± 1.85		
Mortality within 28					
days					
discharged	63 (63.0%)	35 (53.0%)	28 (82.4%)	x <sup>2</sup> = 8.277*	0.004*
Yes	37 (37.0%)	31 (47.0%)	6 (17.6%)		

Figure (1): Relation between mortality within 28 days and type of SVT (n = 66)



### Conclusion

New onset supraventricular arrythmias is frequent during AECOPD and is associated with increased duration of MV, prolonged ICU stays and inpatient mortality